How is Kaiser Permanente different from other health plans when it comes to prescription drugs?
At Kaiser Permanente, we have a value-based, integrated model of care that combines both a health plan and a care delivery system. As a result, we have an innovative approach to prescription drug coverage and purchasing for our members.
Biosimilars at Kaiser Permanente: Lessons in successfully reducing spending on prescription drugs
Biosimilars play a critical role in lowering drug prices. Kaiser Permanente successfully uses biosimilars to improve affordability for our members. We are eager to share best practices and work with policymakers to help facilitate a more competitive market for biologic…
Publications from PORTAL
Kaiser Permanente is proud to partner with the Program on Regulation, Therapeutics, and Law (PORTAL), out of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital/Harvard Medical School, to uncover trends in pharmaceutical evidence generation and highlight the clinical benefits…
Restoring Provider Confidence In FDA-Approved Drugs
The Kaiser Permanente Institute for Health Policy's experts Samantha Dupont, Krysten Joyce and Murray Ross join Kaiser Permanente's Senior Vice President of Government Relations, Tony Barrueta, to share their insights on the policy prescriptions needed to ensure prescribed drugs are…
Evolving nature of evidence required by FDA to approve new drugs
This brief, based on systematic reviews conducted in collaboration with the Program on Therapeutics, And Law (PORTAL), provides background on the evidence required by the Food and Drug Administration (FDA) to support drug approval. It highlights changes in the amount…
Drug policy 101: Kaiser Permanente’s approach to pharmaceutical detailing
As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is critical for policymakers to understand the potential solutions. This brief describes Kaiser Permanente’s approach to providing high-quality, unbiased information to…
Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability
This webinar is the second in a two-part series that looks at racial equity in the drug development system, from investment all the way through access. This forum will focus on equity in the patent system, clinical trials, healthcare delivery, and affordability.
Building a bigger table for a more equitable drug development system
On December 7, 2020, the Kaiser Permanente Institute for Health Policy hosted the first of a 2-part virtual forum examining racial equity in the drug development system, including during initial investments and research, patent and regulatory processes, supplier and physician…